0001562180-20-004471.txt : 20200612 0001562180-20-004471.hdr.sgml : 20200612 20200612200943 ACCESSION NUMBER: 0001562180-20-004471 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200611 FILED AS OF DATE: 20200612 DATE AS OF CHANGE: 20200612 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Doogan Declan CENTRAL INDEX KEY: 0001704234 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38080 FILM NUMBER: 20961708 MAIL ADDRESS: STREET 1: C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP STREET 2: 234 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Biohaven Pharmaceutical Holding Co Ltd. CENTRAL INDEX KEY: 0001689813 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: D8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 BUSINESS PHONE: 203-404-0410 MAIL ADDRESS: STREET 1: 215 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2020-06-11 false 0001689813 Biohaven Pharmaceutical Holding Co Ltd. BHVN 0001704234 Doogan Declan C/O BIOHAVEN PHARMACEUTICALS 215 CHURCH STREET NEW HAVEN CT 06510 true false false false Common Shares 2020-06-11 4 S false 16444.00 61.9672 D 909558.00 I By the Declan Doogan 2014 Trust Common Shares 2020-06-11 4 S false 20043.00 62.7754 D 889515.00 I By the Declan Doogan 2014 Trust Common Shares 2020-06-11 4 S false 18474.00 63.794 D 871041.00 I By the Declan Doogan 2014 Trust Common Shares 2020-06-11 4 S false 25039.00 64.5742 D 846002.00 I By the Declan Doogan 2014 Trust Common Shares 2020-06-12 4 S false 7600.00 62.9279 D 838402.00 I By the Declan Doogan 2014 Trust Common Shares 2020-06-12 4 S false 18400.00 63.9004 D 820002.00 I By the Declan Doogan 2014 Trust Common Shares 2020-06-12 4 S false 28086.00 64.7897 D 791916.00 I By the Declan Doogan 2014 Trust Common Shares 2020-06-12 4 S false 25914.00 65.7849 D 766002.00 I By the Declan Doogan 2014 Trust Common Shares 373913.00 D These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.31 - $62.305, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.31 - $63.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.31 - $64.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.31 - $65.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.32 - $62.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.32 - $64.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.32 - $65.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.32 - $66.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. /s/ Jim Engelhart, Attorney-in-Fact 2020-06-12